We’re proud to share the LinkedIn post from our CEO, Cedric Bogaert, following CureVac’s announcement of U.S. FDA clearance to initiate a Phase 1 clinical trial for an mRNA-based immunotherapy targeting squamous non-small cell lung cancer (sqNSCLC). The clinical candidate includes novel antigens discovered through our collaboration with CureVac.

🚀🚀 It’s been an incredible pleasure working with CureVac to revolutionize cancer immunotherapies. The team has worked tirelessly to design a novel off-the-shelf mRNA cancer vaccine for Squamous Non-Small Cell Lung Cancer (sqNSCLC) patients, and today, we’ve reached a major milestone in its development.

🧫🧬 Over 180,000 people in the US alone will be diagnosed in 2025 with Non-Small Cell Lung Cancer, and 20-30% of those patients will receive the news that they bear the more aggressive form of NSCLC with a high unmet medical need (Squamous NSCLC). This is the target population. Four novel antigens, discovered outside of the standard cancer exome in the myNEO – CureVac collaboration with our AI-powered technology platform, show incredible potential and ensure that our product can cover a broad patient base. There’s currently no need for patient selection before treatment.

⛳ Today, we’re thrilled to share that this immunotherapy has received U.S. FDA clearance to begin a Phase 1 clinical trial. This milestone is a significant step toward revolutionizing cancer therapy and provides new hope for patients with unmet medical needs.

We’re so proud to be part of this journey and so grateful for the opportunity to make a real difference in patients’ lives.

Thank you Alexander Zehnder, MD, MBA and the whole CureVac team involved!

👉 Read CureVac’s official press release here.